CoChat
Sign Up
Cited by 125Gut microbiota and healthGastrointestinal motility and disordersBariatric Surgery and Outcomes

Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials

Open access
Proença, Igor M., Allegretti, Jessica R., Bernardo, Wanderley M., de Moura, Diogo T.H., Ponte Neto, Alberto M., Matsubayashi, Carolina O., Flor, Marcelo M., Kotinda, Ana P.S.T. +1 more·2020·Nutrition Research
DOI 10.1016/j.nutres.2020.06.018
Open this paper in CoChat — free accountOpen PDF

Abstract

Obesity and metabolic syndrome are important health problems that can lead to significant morbidity/mortality as well as subsequent health concerns. Alterations in the gut microbiota have been implicated in both obesity and metabolic syndrome. Fecal Microbiota Transplantation (FMT) has emerged as a new promising therapeutic approach aimed at manipulating the gut microbiota in various chronic diseases. Randomized clinical trials assessing the use of FMT in obese and metabolic syndrome patients have been reported. The purpose of this systematic review with meta-analysis using randomized clinical trials (RCT) is to evaluate the role of FMT for the treatment of obesity and metabolic syndrome and its impact on clinically relevant parameters. We searched the main databases, as well as the gray literature, to identify RCTs comparing FMT from lean donor(s) vs placebo for obese/metabolic syndrome patients. We included all studies that utilized any form of placebo (sham, saline, autologous FMT, or placebo capsules). Six studies met the inclusion criteria and were included for final analysis with a total of 154 patients. We looked for clinically significant parameters related to obesity and metabolic syndrome and organized the findings into early (2-6 weeks after intervention) and late (12 weeks after intervention) outcomes. Two to 6 weeks after intervention, mean HbA1c was lower in the FMT group (MD = -1.69 mmol/L, CI [-2.88, -0.56], P = .003) and mean HDL cholesterol was higher in the FMT group (MD = 0.09 mmol/L, CI [0.02, 0.15], P = .008). There was no difference in obesity parameters 6 to 12 weeks after intervention. No serious adverse events were reported. The findings for this meta-analysis show that FMT may have a role for the treatment of metabolic syndrome, but there is currently not enough evidence to support its use in clinical practice. High-quality well-powered RCTS with longer follow-up are necessary to clarify the role of FMT in this patient cohort.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nutres.2020.06.018

Cites

36 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • After positive outcomes for CDI, FMT has been investigated for a number of chronic disorders associated with dysbiosis, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), metabolic syndrome (MetS), neuropsychiatric disorders, and others.

    “After positive outcomes for CDI, FMT has been investigated for a number of chronic disorders associated with dysbiosis, including inflammatory bowel disease (IBD), 35 irritable bowel syndrome (IBS), 36 metabolic syndrome (MetS), 37 neuropsychiatric disorders, 38 andothers.”

    From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [37]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra A V, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab 2017;26:611-619.e6. https://doi.org/10.1016/j.cmet.2017.0 9.008. · DOI · Paper page

Cited by

Sorted by citations

Related

Authors
Proença, I. M., Allegretti, J. R., Bernardo, W. M., de Moura, D. T. H., Ponte Neto, A. M., Matsubayashi, C. O., Flor, M. M., Kotinda, A. P. S. T., & de Moura, E. G. H.
Affiliations
  • Brigham and Women's Hospital (US)
  • Universidade de São Paulo (BR)
ORCID
Venue
Nutrition Research
Publisher
Elsevier BV
Published
2020-11
Volume
83
Pages
1-14
ISSN
0271-5317 (ISSN-L)
DOI
10.1016/j.nutres.2020.06.018
OpenAlex
W3039741090
Cited by
124
References
36
Citations by year
2026: 25 · 2025: 19 · 2024: 18 · 2023: 29 · 2022: 17 · 2021: 15 · 2020: 1
FWCI
1.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Nutrition Research (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
fecal microbiota transplantation, metabolic syndrome, obesity, gut microbiota, HbA1c, HDL cholesterol, glycemic control, dyslipidemia
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Blood Glucose, Cholesterol, Female, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Obesity, Randomized Controlled Trials as Topic, Treatment Outcome, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review